688180 Shanghai Junshi Biosciences Co., Ltd.
- 29.42
- -1.00-3.29%
Shanghai Junshi Biosciences Co., Ltd. News
Junshi Biotech\'s announcement on changing the implementing entity of the fund-raising project
Announcement of Junshi Biotech regarding the death of Mr. Shen Jingkang, an independent non-executive director
Junshi Biotech voluntarily disclosed an announcement regarding the approval for marketing of treprilizumab in Hong Kong, China
Junshi Biotech voluntarily discloses an announcement on approval of the marketing application for a new drug with angerisimab injection
Junshi Biotech: Junshi Biotech\'s announcement on the signing of a license and cooperation agreement between its holding subsidiary and Jisheng Aoma
Announcement of Junshi Biotech on the signing of licensing and cooperation agreements between its holding subsidiary and Jisheng Aoma
Junshi Biotech voluntarily disclosed the announcement that treprilizumab was approved for marketing by the European Commission
Junshi Biotech\'s announcement on the use of its own funds to pay for fund-raising project personnel fees, the use of its own foreign exchange and bank acceptance notes to pay the funds required for the fund-raising project, and replace the funds raised in equal amounts
Junshi Biotech\'s announcement on capital cuts and related transactions of participating companies
Junshi Bio voluntarily disclosed a public announcement regarding the acceptance of its application for a new indication for Trelagliptin single antibody first-line treatment of melanoma.
Junshi Bio voluntarily disclosed the announcement about the positive opinion received by Tirzepatide from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Junshi Biosciences voluntarily disclosed an announcement regarding the acceptance of the market application for the new indication of combination therapy of Toripalimab and Bevacizumab for first-line treatment of advanced liver cancer.
Junshi Bio voluntarily disclosed an announcement regarding its wholly-owned subsidiary passing EU GMP certification.
Junshi Bio voluntarily discloses the announcement about JS125 obtaining the drug clinical trial application acceptance notice.
Junshi Bio voluntarily discloses the announcement of the approval of the new indication for Teriprizumab monoclonal antibody for first-line treatment of advanced Triple-Negative Breast Cancer.
Announcement from Junshi Bio regarding the election of the fourth session of the Supervisor Employees' Representative Supervisor.
Legal Opinion of Jia Yuan Law Firm in Beijing on the 2023 Annual Shareholders' Meeting, 2024 First A-Share Category Shareholders' Meeting and 2024 First H-Share Category Shareholders' Meeting of Junshi Bio-medical Technology Co., Ltd. in Shanghai
Junshi Bio announces the resolutions of the 2023 Annual General Meeting of Shareholders, the first A-share category Shareholders' Meeting in 2024, and the first H-share category Shareholders' Meeting in 2024.
Announcement from Junshi Bio regarding the election of Chairman, Vice Chairman, Committee Members of the Board of Directors, Chairman of the Supervisory Board, and appointment of senior management personnel.
Junshi Bio voluntarily disclosed the announcement of the approval of the new indication for the use of Trelagliptin monoclonal antibody in the first-line treatment of extensive-stage small cell lung cancer.
Analysis
Price Target
No Data
No Data